18:14 , Feb 15, 2019 |  BC Week In Review  |  Company News

Samsung Bioepis partners with AffaMed, expands biosimilar development in China

Samsung Bioepis Co. Ltd. (Incheon, South Korea) partnered to develop four of its biosimilars with AffaMed Therapeutics (Shanghai, China). The partners will initially collaborate on clinical development, regulatory registration and commercialization Ontruzant, SB11, SB12 and...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big...
07:00 , May 23, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/20 cls Arbutus Biopharma Corp. (NASDAQ:ABUS) Chardan Capital Madhu Kumar New Sell -6% $4.08 Kumar initiated coverage with a $3.25...
07:00 , May 16, 2016 |  BC Week In Review  |  Company News

Epirus biosimilars, hematology, cancer news

Epirus will reduce headcount by 40% to reprioritize its pipeline to focus exclusively on developing biosimilars for rare diseases. The company will suspend development of its Phase III-ready lead program BOW015 , a biosimilar of...
07:00 , Sep 14, 2015 |  BC Week In Review  |  Company News

Bioceros, Epirus deal

Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) markets Simponi and Stelara to treat autoimmune diseases. Epirus would not disclose when the company plans to begin clinical testing for the acquired biosimilars. Bioceros B.V. , Utrecht,...
01:19 , Sep 10, 2015 |  BC Extra  |  Company News

Epirus nabs biosimilars in Bioceros takeout

Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS) acquired biosimilars company Bioceros B.V. (Utrecht, the Netherlands) for $14.1 million in cash and stock to be paid over a one-year period. Epirus gains three preclinical candidates: BOW080, a biosimilar of...